Is the Galleri multi-cancer blood test worth it? A doctor explains real-world performance data and explains why no major ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline results from the landmark, randomized, controlled NHS-Galleri ...

Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to ...

Feb 20 (Reuters) - Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

GRAIL Inc. GRAL shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial ...

Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...

GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.

Grail (GRAL) shares plunge after NHS-Galleri results missed primary endpoint but showed fewer Stage IV cases in 12 deadly ...

Add Yahoo as a preferred source to see more of our stories on Google. Pancreatic cancer is the third leading cause of cancer-related deaths, trailing behind lung cancer and colorectal cancer, a trend ...